NCT02411448 2026-01-16
RELAY
Eli Lilly and Company
Phase 3 Active not recruiting
Clinical Trials
49 trialsNCT02296125 2026-01-09
FLAURA
AstraZeneca
Phase 3 Completed
NCT03292133 2025-06-10
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT00328562 2025-05-04
ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer
Thomas Jefferson University
Phase 1 Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT02588261 2024-12-10
SOLAR
Astellas Pharma Inc
Phase 3 Terminated
NCT04248829 2024-12-03
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
Yuhan Corporation
Phase 3 Active not recruiting
NCT01513174 2024-06-28
GOAL
Spanish Lung Cancer Group
Phase 1/2 Completed
NCT01774721 2023-11-14
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
Pfizer
Phase 3 Completed
NCT00483561 2023-09-13
Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy
University of Nebraska
Phase 2 Terminated
NCT04179890 2023-05-25
UpSwinG
Boehringer Ingelheim
Completed
NCT01185171 2023-05-11
Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer
University of Chicago
Phase 2 Completed
NCT03599518 2023-02-08
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
Daiichi Sankyo
Phase 1 Terminated
NCT03849768 2023-01-20
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT02039674 2022-11-08
MK-3475-021
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT01610336 2021-04-08
A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Novartis
Phase 2 Completed
NCT01466660 2020-04-07
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Boehringer Ingelheim
Phase 2 Completed
NCT01469000 2019-09-10
A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 2 Completed
NCT00126555 2019-08-30
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02179671 2019-08-02
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
AstraZeneca
Phase 2 Completed
NCT00493025 2018-12-06
Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00509002 2017-11-24
Iressa Study in Patients With Salivary Gland Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00095836 2017-05-31
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Massachusetts General Hospital
Phase 2 Completed
NCT01310855 2017-05-31
Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma
University College, London
Phase 2 Terminated
NCT00086957 2017-02-27
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT01404260 2017-01-27
ISCAN
Guangdong Association of Clinical Trials
Phase 3 Completed
NCT01203917 2017-01-02
IFUM
AstraZeneca
Phase 4 Completed
NCT00519077 2016-07-01
Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck
University of Chicago
Phase 2 Completed
NCT01530334 2016-02-23
ICARUS
AstraZeneca
Phase 2 Completed
NCT00770588 2016-02-08
INFORM
AstraZeneca
Phase 4 Completed
NCT00588445 2016-01-22
Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00085566 2016-01-20
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00268346 2016-01-05
Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00479089 2015-11-02
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01017874 2015-07-08
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
Eli Lilly and Company
Phase 3 Completed
NCT00088907 2015-05-06
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00054691 2015-03-13
ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00049543 2015-01-01
Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00057941 2014-05-12
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00536107 2013-10-01
Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
AstraZeneca
Phase 4 Terminated
NCT00824746 2013-02-26
ReGaiN
Chonnam National University Hospital
Phase 2 Completed
NCT00352105 2012-11-05
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT00104728 2012-10-31
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated
NCT00608868 2012-09-28
SELINE
AstraZeneca
Phase 4 Completed
NCT00113529 2011-08-29
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
Pfizer
Phase 1/2 Completed
NCT00409006 2010-09-09
Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers
Eli Lilly and Company
Phase 2 Completed
NCT00344773 2010-06-29
First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
AstraZeneca
Phase 2 Completed
NCT00229723 2009-08-04
IRESSAâ„¢ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 2 Completed
NCT00264498 2009-08-03
Phase II Iressa & Carbo/Gem in NSCLC
AstraZeneca
Phase 2 Completed